Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07673029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Name: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer — clinical trial record (NCT07673029)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorGeneQuantum Healthcare (Suzhou) Co., Ltd.

Started2025-01-10

View on ClinicalTrials.gov ↗

GeneQuantum Healthcare (Suzhou) Co., Ltd.

2 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Trial Details

NCT Number	NCT07673029
Lead Sponsor	GeneQuantum Healthcare (Suzhou) Co., Ltd.
Conditions	HER2-positive Breast Cancer
Enrollment	228 participants
Start Date	2025-01-10
Primary Completion	2027-01-09 (estimated)
Study Completion	2028-01-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-29